| Identification | Back Directory | [Name]
CBS9106 (BMS566419) | [Synonyms]
SL-801
S-03747
CBS-9106
CBS9106 (BMS566419)
Felezonexor，CBS9106
1-[[6-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-3-(3,3-dimethylbutoxymethyl)-4-methylpyrrole-2,5-dione
1-((6-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-3-((3,3-dimethylbutoxy)methyl)-4-methyl-1H-pyrrole-2,5-dione
1H-Pyrrole-2,5-dione, 1-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-3-[(3,3-dimethylbutoxy)methyl]-4-methyl- | [MDL Number]
MFCD28502170 | [MOL File]
1076235-04-5.mol |
| Hazard Information | Back Directory | [Uses]
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities. CBS9106, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells[1]. | [in vivo]
CBS9106 (31.25-62.5 mg/kg for 5 times weekly, 125 mg/kg for 3 times weekly; p.o.; 2 weeks) significantly suppresses tumor growth at dose levels of 62.5 or 125 mg/kg in mice bearing human MM xenograft models[1]. | Animal Model: | SCID mice with RPMI-8226 cells[1] | | Dosage: | 31.25, 62.5, 125 mg/kg | | Administration: | Oal administration; 5 times weekly (31.25 and 62.5 mg/kg), 3 times weekly (125 mg/kg); 2 weeks | | Result: | Showed statistically significant tumor growth inhibition at dose levels of 62.5 mg/kg or 125 mg/kg. |
| [References]
[1] Sakakibara K, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 6;118(14):3922-31. DOI:10.1182/blood-2011-01-333138 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|